查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
帕金森氏症治療藥的全球市場:市場規模 - 各年齡層，各藥物類別，各給藥途徑，各地區展望，競爭策略，各市場區隔預測(～2032年)
市場調查報告書
商品編碼
1159580

帕金森氏症治療藥的全球市場:市場規模 - 各年齡層，各藥物類別，各給藥途徑，各地區展望，競爭策略，各市場區隔預測(～2032年)

Parkinson's Disease Drugs Market Size- By Age Group, By Drug Class, By Route of Administration - Regional Outlook, Competitive Strategies and Segment Forecasts to 2032
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 246 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球帕金森氏症治療藥的市場規模，預計至2032年達到109億3,000萬美元，以6.5％的年複合成長率成長。

促進市場成長的重要要素，是帕金森氏症的患者數多與診斷率的提高。主要企業對帕金森氏症治療藥的研究開發投資增加，及老年人口增加，成為產業促進成長因素之一。

本報告提供全球帕金森氏症治療藥市場相關調查，市場動態，市場變數及預測，年齡層、藥物類別、給藥途徑、各地區的市場分析，企業簡介等相關資訊。

目錄

第1章 簡介

  • 調查範圍
  • 市場區隔分析

第2章 調查手法

  • 調查資料來源
  • 市場規模的估計
  • 資料的三角測量

第3章 摘要整理

第4章 市場動態

  • 促進因素，阻礙因素，機會，課題的分析
    • 促進因素
    • 阻礙因素
    • 機會
    • 課題
  • 全球帕金森氏症治療藥市場上COVID-19的影響

第5章 市場變數及預測

  • SWOT分析
    • 優勢
    • 弱點
    • 機會
    • 威脅
  • PESTEL分析
    • 政治形勢
    • 經濟形勢
    • 社會形勢
    • 技術形勢
    • 環境形勢
    • 法律上的形勢
  • 波特的五力分析
    • 供給企業談判力
    • 買方議價能力
    • 替代品的威脅
    • 新加入廠商的威脅
    • 競爭企業間的敵對關係
  • 熱圖分析

第6章 全球帕金森氏症治療藥市場:各年齡層，2019年～2032年(100萬美元)

  • 50歲以下
  • 50歲以上

第7章 全球帕金森氏症治療藥市場:各藥物類別，2019年～2032年(100萬美元)

  • 脫羧酶抑制劑
  • 多巴胺促效劑
  • COMT抑制劑
  • MAO-B抑制劑
  • 其他

第8章 全球帕金森氏症治療藥市場:各給藥途徑，2019年～2032年(100萬美元)

  • 注射
  • 口服
  • 經皮

第9章 全球帕金森氏症治療藥市場:各地區，2019年～2032年(100萬美元)

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他的歐洲
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 其他的亞太地區
  • 南美
    • 巴西
    • 阿根廷
    • 其他的南美
  • 中東、非洲
    • 沙烏地阿拉伯王國
    • 阿拉伯聯合大公國
    • 其他的中東、非洲

第10章 企業簡介

  • AbbVie Inc.
    • 企業概要
    • 財務預測
    • 產品概要
    • 最近的開發
  • Amneal Pharmaceuticals, Inc.
  • Biogen Inc., C.H.
  • Boehringer Sohn Ko. KG
  • Eli Lilly and Company
  • F.Hoffmann-La Roche Ltd
  • Gentech Healthcare
  • GlaxoSmithKline Plc
  • Intas Pharmaceuticals Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Orion Corporation
  • Pfizer Inc.
  • Square group
  • Sun Pharmaceutical Industries
  • Teva Pharmaceuticals
  • Torrent Group
  • UCB
  • Viatris Inc.
簡介目錄
Product Code: PHAR2209

Global Parkinson's Disease Drugs Market Overview:

According to SPER Market Research, the Global Parkinson's Disease Drugs Market is estimated to reach USD 10.93 billion by 2032 with a CAGR of 6.5%.

Parkinson's Disease, also known as idiopathic Parkinsonism, is a neurodegenerative disease. It is a progressive disease that affects both the neurological system and the bodily components controlled by the nervous system. Dopamine is produced in the substantia nigra region of the brain. Dopamine levels decrease in Parkinson's Disease as substantial cells in the brain begin to die. Parkinson's Disease may be caused by environmental or genetic factors. Those with an affected family member are at a higher risk of contracting the disease, as certain genes are known to be inheritable risk factors. Tremors, slowed movement, rigid muscles, impaired posture and balance, speech changes, and other symptoms are common. Non-motor symptoms usually appear gradually, and as the disease progresses, they become more common. Age is the most important risk factor, but other factors such as environment and heredity also play a role.

Significant factors driving market growth include a large patient pool and an increasing rate of diagnosis. According to the Parkinson's Disease Foundation, nearly 10 million people worldwide suffer from this disorder. This disorder is most common in developed countries, with nearly 60,000 new cases reported each year in the United States. Demand for Parkinson's Disease drugs is expected to rise globally during the forecast period, owing to an increase in the geriatric population, which drives the market growth. Furthermore, increases in R&D investments by key players in Parkinson's Disease drugs, as well as an increase in the geriatric population, are some factors driving the growth of the Parkinson's Disease drugs industry. The COMT inhibitors are expected to grow at the fastest rate during the forecast period due to advantages such as long-lasting enzyme inhibition, reduced adverse effects of drugs, and lower levodopa dose. The oral route of administration is expected to grow the fastest during the forecast period, owing to more pre-determined doses, convenience, and patient self-administration. The over-50 age group is expected to continue this trend during the forecast period. This is due to an aging population, as age is a risk factor for Parkinson's Disease, which increases the over-50 age group. However, the side effects of Parkinson's Disease drugs may limit the market growth.

Impact of COVID-19 on the Global Parkinson's Disease Drugs Market

The global Parkinson's Disease drugs market fell in 2020 as a result of the global economic recession caused by COVID-19. However, the market will recover in the forecast period as a result of increased Parkinson's Disease drug adoption and an increase in Parkinson's Disease drug R&D pipeline products.

Scope of the Report:

Market size available for years 2019-2032

Base year considered 2021

Forecast period 2022-2032

Segments covered By Age group, By Drug Class, By Route of administration

Geographies covered: North America, Europe, Asia Pacific, Latin America, Middle East and Africa

Companies Covered AbbVie Inc., Amneal Pharmaceuticals, Inc., Biogen Inc., C.H., Boehringer Sohn Ko. KG, Eli Lilly and Company, F.Hoffmann-La Roche Ltd., Gentech Healthcare, GlaxoSmithKline Plc, Intas Pharmaceuticals Limited, Merck & Co., Inc., Novartis AG, Orion Corporation, Pfizer Inc., Square group, Sun Pharmaceutical Industries, Teva Pharmaceuticals, Torrent Group, UCB, Viatris Inc.

Global Parkinson's Disease Drugs Market Segmentation:

By Age Group: Based on the Age Group, Global Parkinson's Disease Drugs Market is segmented as; 50 or below 50 (Key market trends, growth factors and opportunities, Market size and forecast, Market analysis by Region), Above 50 years (Key market trends, growth factors and opportunities, Market size and forecast, Market analysis by Region).

By Drug Class: Based on the Drug Class, Global Parkinson's Disease Drugs Market is segmented as; Decarboxylase Inhibitors {Key market trends, growth factors and opportunities, Market size and forecast, Market analysis by Region, Decarboxylase Inhibitors Parkinson's Disease Drugs Market by Distribution Channel (Hospital Pharmacies Market size and forecast, by region, Drug stores and Retail Pharmacies Market size and forecast, by region, Online Providers Market size and forecast, by region), Dopamine Agonists (Key market trends, growth factors and opportunities, Market size and forecast, Market analysis by Region), COMT Inhibitors (Key market trends, growth factors and opportunities, Market size and forecast, Market analysis by Region), MAO-B Inhibitors (Key market trends, growth factors and opportunities, Market size and forecast, Market analysis by Region), Others.

By Route of Administration: Based on the ROA, Global Parkinson's Disease Drugs Market is segmented as; Injectable (Key market trends, growth factors and opportunities, Market size and forecast, Market analysis by Region), Oral (Key market trends, growth factors and opportunities, Market size and forecast, Market analysis by Region), Transdermal (Key market trends, growth factors and opportunities, Market size and forecast, Market analysis by Region).

By Region: During the forecast period, North America is expected to dominate the Parkinson's Disease drugs market, accounting for the largest share. This is due to factors such as the presence of key players in the region and the availability of diagnostic laboratories. Furthermore, high-quality healthcare in the United States is expected to drive the growth of the North American market.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Global Parkinson's Disease Drugs Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Global Parkinson's Disease Drugs Market, By Age Group, 2019-2032 (USD Million)

  • 6.1. 50 or below 50
    • 6.1.1. Key market trends, growth factors and opportunities
    • 6.1.2. Market size and forecast
    • 6.1.3. Market analysis by Region
  • 6.2. Above 50 years
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast
    • 6.2.3. Market analysis by Region

7. Global Parkinson's Disease Drugs Market, By Drug Class, 2019-2032 (USD Million)

  • 7.1. Decarboxylase Inhibitors
    • 7.1.1. Key market trends, growth factors and opportunities
    • 7.1.2. Market size and forecast
    • 7.1.3. Market analysis by Region
    • 7.1.4. Decarboxylase Inhibitors Parkinson's Disease Drugs Market by Distribution Channel
      • 7.1.4.1 Hospital Pharmacies Market size and forecast, by region
      • 7.1.4.2 Drug stores and Retail Pharmacies Market size and forecast, by region
      • 7.1.4.3 Online Providers Market size and forecast, by region
  • 7.2. Dopamine Agonists
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast
    • 7.2.3. Market analysis by Region
  • 7.3. COMT Inhibitors
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast
    • 7.3.3. Market analysis by Region
  • 7.4. MAO-B Inhibitors
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast
    • 7.4.3. Market analysis by Region
  • 7.5. Others
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast
    • 7.5.3. Market analysis by Region

8. Global Parkinson's Disease Drugs Market, By Route of Administration, 2019-2032 (USD Million)

  • 8.1. Injectable
    • 8.1.1. Key market trends, growth factors and opportunities
    • 8.1.2. Market size and forecast
    • 8.1.3. Market analysis by Region
  • 8.2. Oral
    • 8.2.1. Key market trends, growth factors and opportunities
    • 8.2.2. Market size and forecast
    • 8.2.3. Market analysis by Region
  • 8.3. Transdermal
    • 8.3.1. Key market trends, growth factors and opportunities
    • 8.3.2. Market size and forecast
    • 8.3.3. Market analysis by Region

9. Global Parkinson's Disease Drugs Market, By Region, 2019-2032 (USD Million)

  • 9.1. North America
    • 9.1.1. United States
    • 9.1.2. Canada
    • 9.1.3. Mexico
  • 9.2. Europe
    • 9.2.1. Germany
    • 9.2.2. United Kingdom
    • 9.2.3. France
    • 9.2.4. Italy
    • 9.2.5. Spain
    • 9.2.6. Rest of Europe
  • 9.3. Asia-Pacific
    • 9.3.1. China
    • 9.3.2. Japan
    • 9.3.3. India
    • 9.3.4. Australia
    • 9.3.5. South Korea
    • 9.3.6. Rest of Asia-Pacific
  • 9.4. South America
    • 9.4.1. Brazil
    • 9.4.2. Argentina
    • 9.4.3. Rest of South America
  • 9.5. Middle East & Africa
    • 9.5.1. Kingdom of Saudi Arabia
    • 9.5.2. United Arab Emirates
    • 9.5.3. Rest of Middle East & Africa

10. Company Profiles

  • 10.1. AbbVie Inc.
    • 10.1.1. Company details
    • 10.1.2. Financial outlook
    • 10.1.3. Product summary
    • 10.1.4. Recent developments
  • 10.2. Amneal Pharmaceuticals, Inc.
    • 10.2.1. Company details
    • 10.2.2. Financial outlook
    • 10.2.3. Product summary
    • 10.2.4. Recent developments
  • 10.3. Biogen Inc., C.H.
    • 10.3.1. Company details
    • 10.3.2. Financial outlook
    • 10.3.3. Product summary
    • 10.3.4. Recent developments
  • 10.4. Boehringer Sohn Ko. KG
    • 10.4.1. Company details
    • 10.4.2. Financial outlook
    • 10.4.3. Product summary
    • 10.4.4. Recent developments
  • 10.5. Eli Lilly and Company
    • 10.5.1. Company details
    • 10.5.2. Financial outlook
    • 10.5.3. Product summary
    • 10.5.4 Recent developments
  • 10.6. F.Hoffmann-La Roche Ltd.
    • 10.6.1. Company details
    • 10.6.2. Financial outlook
    • 10.6.3. Product summary
    • 10.6.4. Recent developments
  • 10.7. Gentech Healthcare
    • 10.7.1. Company details
    • 10.7.2. Financial outlook
    • 10.7.3. Product summary
    • 10.7.4. Recent developments
  • 10.8. GlaxoSmithKline Plc
    • 10.8.1. Company details
    • 10.8.2. Financial outlook
    • 10.8.3. Product summary
    • 10.8.4. Recent developments
  • 10.9. Intas Pharmaceuticals Limited
    • 10.9.1. Company details
    • 10.9.2. Financial outlook
    • 10.9.3. Product summary
    • 10.9.4. Recent developments
  • 10.10. Merck & Co., Inc.
    • 10.10.1. Company details
    • 10.10.2. Financial outlook
    • 10.10.3. Product summary
    • 10.10.4. Recent developments
  • 10.11 Novartis AG
    • 10.11.1. Company details
    • 10.11.2. Financial outlook
    • 10.11.3. Product summary
    • 10.11.4. Recent developments
  • 10.12. Orion Corporation
    • 10.12.1. Company details
    • 10.12.2. Financial outlook
    • 10.12.3. Product summary
    • 10.12.4. Recent developments
  • 10.13. Pfizer Inc.
    • 10.13.1. Company details
    • 10.13.2. Financial outlook
    • 10.13.3. Product summary
    • 10.13.4. Recent developments
  • 10.14. Square group
    • 10.14.1. Company detail
    • 10.14.2. Financial outlook
    • 10.14.3. Product summary
    • 10.14.4. Recent developments
  • 10.15. Sun Pharmaceutical Industries
    • 10.15.1. Company details
    • 10.15.2. Financial outlook
    • 10.15.3. Product summary
    • 10.15.4. Recent developments
  • 10.16. Teva Pharmaceuticals
    • 10.16.1. Company details
    • 10.16.2. Financial outlook
    • 10.16.3. Product summary
    • 10.16.4. Recent development
  • 10.17. Torrent Group
    • 10.17.1. Company details
    • 10.17.2. Financial outlook
    • 10.17.3. Product summary
    • 10.17.4. Recent development
  • 10.18. UCB
    • 10.18.1. Company details
    • 10.18.2. Financial outlook
    • 10.18.3. Product summary
    • 10.18.4. Recent development
  • 10.19. Viatris Inc.
    • 10.19.1. Company details
    • 10.19.2. Financial outlook
    • 10.19.3. Product summary
    • 10.19.4. Recent development